Education
About Us
Working with TipRanks
Follow Us
Mereo Biopharma Group Plc (MREO)
NASDAQ:MREO
MREO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.22 - $5.02
Previous CloseN/A
Volume219.93K
Average Volume (3M)1.29M
Market Cap
$372.91M
Enterprise Value$479.64M
Total Cash (Recent Filing)$56.33M
Total Debt (Recent Filing)$12.77M
Price to Earnings (P/E)―
Beta1.04
Next Earnings
May 14, 2025EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.29
Shares Outstanding155,145,600
10 Day Avg. Volume813,494
30 Day Avg. Volume1,291,166
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)36.04
Price to Cash Flow (P/CF)-32.70
P/FCF Ratio0.00
Enterprise Value/Market Cap1.29
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit64.59
Enterprise Value/Ebitda-11.35
Forecast
1Y Price Target
$7.40Price Target Upside207.05% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
---
Mereo Biopharma Group Plc News
PremiumCompany Announcements
Mereo BioPharma Reports 2024 Financial Results and Progress
PremiumCompany Announcements
Mereo Biopharma Advances with Key Clinical Updates
---
Bulls Say, Bears Say
Bulls Say
Drug DevelopmentSetrusumab has already demonstrated a differentiated safety profile and compelling efficacy in Phase 2b that was maintained through approximately 16 months.
Financial StrategyMereo is currently evaluating non-dilutive financing options for the alvelestat program, which is viewed as another possible upside lever.
Market OpportunityLow competition risk for setrusumab in osteogenesis imperfecta seems underappreciated.
Bears Say
Execution RiskThe company is actively seeking strategic partners to advance clinical development of alvelestat in AATD.
Valuation ConcernsRecent stock weakness could represent a buying opportunity ahead of topline results from the ongoing Phase 3 ORBIT in osteogenesis imperfecta.
---
Ownership Overview
1.34% Insiders
0.10% Mutual Funds
48.03% Other Institutional Investors
49.96% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
MREO FAQ
What was Mereo Biopharma Group Plc’s price range in the past 12 months?
Mereo Biopharma Group Plc lowest stock price was $2.22 and its highest was $5.02 in the past 12 months.
What is Mereo Biopharma Group Plc’s market cap?
Mereo Biopharma Group Plc’s market cap is $372.91M.
When is Mereo Biopharma Group Plc’s upcoming earnings report date?
Mereo Biopharma Group Plc’s upcoming earnings report date is May 14, 2025 which is in 46 days.
How were Mereo Biopharma Group Plc’s earnings last quarter?
Mereo Biopharma Group Plc released its earnings results on Mar 26, 2025. The company reported -$0.01 earnings per share for the quarter, beating the consensus estimate of -$0.013 by $0.003.
Is Mereo Biopharma Group Plc overvalued?
According to Wall Street analysts Mereo Biopharma Group Plc’s price is currently Undervalued.
Does Mereo Biopharma Group Plc pay dividends?
Mereo Biopharma Group Plc does not currently pay dividends.
What is Mereo Biopharma Group Plc’s EPS estimate?
Mereo Biopharma Group Plc’s EPS estimate is >-0.01.
How many shares outstanding does Mereo Biopharma Group Plc have?
Mereo Biopharma Group Plc has 155,145,600 shares outstanding.
What happened to Mereo Biopharma Group Plc’s price movement after its last earnings report?
Mereo Biopharma Group Plc reported an EPS of -$0.01 in its last earnings report, beating expectations of -$0.013. Following the earnings report the stock price went up 0.851%.
Which hedge fund is a major shareholder of Mereo Biopharma Group Plc?
Currently, no hedge funds are holding shares in MREO
---
Mereo Biopharma Group Plc Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.40 (207.05% Upside)
$7.40 (207.05% Upside)
Blogger Sentiment
Bullish
MREO Sentiment 66%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 844.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▼ 9.2%
Last 30 Days ▼ 9.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Company Description
Mereo Biopharma Group Plc
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency. The company has a collaboration with The University of Texas MD Anderson Cancer Center to evaluate anti-TIGIT therapeutic antibody candidate, etigilimab. Mereo BioPharma Group plc was incorporated in 2015 and is based in London, the United Kingdom.
---
MREO Stock 12 Month Forecast
Average Price Target
$7.40
▲(207.05% Upside)
Technical Analysis
Eloxx Pharmaceuticals
―
Cara Therapeutics
―
Ardelyx
―
Viking Therapeutics
―
AnaptysBio
―
Best Analysts Covering MREO
1 Year
1 Year Success Rate
9/14 ratings generated profit
1 Year Average Return
+72.90%
reiterated a buy rating 3 months ago
Copying Joseph Schwartz's trades and holding each position for 1 Year would result in 64.29% of your transactions generating a profit, with an average return of +72.90% per trade.
---